Abstract:TPS5107 Background: CD105 (endoglin) is a co-receptor for the transforming growth factor-beta (TGF-β) receptor family. TGF-β signaling is activated in response to castration and is a determinant of PCa epithelial cell death in response to castration. In prostate cancer, silencing of TGF-ß receptor type 2 (Tgfbr2) in cancer-associated fibroblasts (CAF) potentiates tumor progression and castrate resistance primarily by paracrine signaling mechanisms mediated by the bone morphogenic protein (BMP)-SMAD axis. Upregulation of CD105 is observed in the face of progression through AR suppression and can drive pro-survival, pro-metastatic pathways BMP-SMAD signaling. This is accompanied with an increase in neural differentiation and the generation of AR-splice variants. In model systems, suppression of CD105-mediated signaling reversed these behaviors and resorted sensitivity to AR suppression. Carotuximab is a humanized monoclonal antibody that potently inhibits CD105-mediated signaling. It was originally developed for clinical use as an anti-angiogenic agent and was found to have an acceptable toxicity profile. Given our previous work, we hypothesized that use of CD105 will restore sensitivity to AR inhibition in men who have developed early resistance to an AR signaling inhibitor (ARSI) that would result in a synthetic lethality from combination treatment that will manifest as an extension of progression free survival when compared to ARSI therapy alone. Methods: This study (NCT05534646) is open to men with metastatic, castration-resistant prostate cancer who have progressed on previous ARSI therapy. Patients with recent thrombotic and/or cardiovascular events are excluded. Patients are allowed to have had prior docetaxel only in the setting of castration sensitive disease. The study includes a safety lead-in of 10 patients on combination therapy based on our previous work with carotuximab with other ARSI in NCT03418324. This will ensure that the probability of starting the phase 2 dose with a safe dose is sufficiently high. The study then proceeds to a (1:1) randomized study of apalutamide with or without carotuximab (n = 90). Patients randomized to apalutamide alone are permitted to cross over to combination therapy at the time of radiographic progression. The primary endpoint of the study is radiographic progression free survival (rPFS) and is designed to detect a 45% difference in rPFS in the two arms with 81% power and two-sided alpha of 0.10. This study also includes extensive correlative studies focusing on circuating tumor cells and extracellular vesicles which will be enriched and studies using novel nanotechnology enabled methodologies from our group as well as cell free DNA studies which will be used identify those patients with the greatest benefits from this form of therapy to expedite the development of this therapeutic approach. Clinical trial information: NCT05534646 .

A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma – the DUCT study protocol

A randomized phase II study of apalutamide with or without carotuximab (ant-CD105) in metastatic, castration-resistant prostate cancer.

The extent of androgen receptor and HER2 expression allows for targeted therapy in most cases of salivary duct carcinoma: analysis of clinical and histopathological data in a tertiary care center

BTCRC-HN17-111, A phase 2 trial of ADT (goserelin) in combination with pembrolizumab for patients with advanced salivary gland tumors expressing androgen receptor (AR).

A Phase II Umbrella Clinical Trial of Advanced Salivary Gland Cancer Based on Molecular Typing.

A randomized, non-comparative, phase II multicentric trial on short-term darolutamide (ODM-201) concomitant to radiation therapy for patients with unfavorable intermediate-risk prostate cancer: DARIUS (AFU-GETUG P15).

A phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate cancer: ARAMON study.

Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration Resistant Prostate Cancer.

Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) by disease volume and disease risk in the phase 3 ARASENS study.

Nivolumab as a Promising Treatment Option for Metastatic Salivary Duct Carcinoma

Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma

Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial)

Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial

A Phase 1b Adaptive Androgen Deprivation Therapy Trial in Metastatic Castration Sensitive Prostate Cancer

Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO)

Overall survival with darolutamide vs placebo in combination with androgen-deprivation therapy (ADT) and docetaxel: A sensitivity analysis from ARASENS accounting for subsequent therapy.

Radiotherapy as salvage treatment of salivary duct carcinoma in major salivary glands without radical operations.

Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol

Lutetium-177-PSMA therapy for recurrent/metastatic salivary gland cancer: a prospective pilot study

A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer

Dissecting the immune infiltrate induced by ADT and PD-1 blockade in men with metastatic hormone-sensitive prostate cancer using single-cell RNA-sequencing.